Objective:

To examine the impact of thoracic radiation therapy on cardiac and immune system toxicities in patients with non-small cell lung cancer (NSCLC) and propose future research directions, emphasizing the significance of these findings for improving patient outcomes.

Key Findings:

• Higher radiation doses to the heart are associated with increased mortality in NSCLC patients, highlighting the need for careful treatment planning.
• Mean heart dose (MHD) correlates with high-grade cardiac events and all-cause mortality, suggesting a need for monitoring MHD in clinical practice.
• Specific cardiac substructures, such as the sinoatrial node and coronary vessels, are linked to worse survival outcomes, indicating areas for targeted intervention.
• Volume-based dosimetry to the pulmonary artery is associated with poorer overall survival, warranting further investigation into its clinical implications.
• Discrepancies in survival rates in the RTOG 0617 trial cannot be fully explained by cardiac deaths alone, suggesting other contributing factors.

Interpretation:

Thoracic RT not only serves as an ablative local therapy but may also act as a systemic immune modulator, impacting immune system integrity and necessitating a reevaluation of treatment strategies.

Limitations:

• The review primarily focuses on retrospective studies, which may introduce bias; further investigation is needed to understand the complex interplay between cardiac toxicity and immune response.

Conclusion:

Future research should explore immune-sparing techniques in radiation planning to preserve immune system integrity in NSCLC treatment, reinforcing the importance of these findings in current clinical practice.